(1->4)-beta-D-glucan multiple interactions ISO RGD:1319184 6480464 [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of CYLD mRNA CTD PMID:36331819 1,2-dimethylhydrazine decreases expression ISO RGD:1319184 6480464 1, 2-Dimethylhydrazine results in decreased expression of CYLD mRNA CTD PMID:22206623 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1319184 6480464 Tetrachlorodibenzodioxin results in decreased expression of CYLD mRNA CTD PMID:15328365 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of CYLD mRNA CTD PMID:34747641 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of CYLD mRNA CTD PMID:32109520 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1319184 6480464 Tetrachlorodibenzodioxin affects the expression of CYLD mRNA CTD PMID:21570461 3,4-methylenedioxymethamphetamine decreases expression ISO RGD:1319184 6480464 N-Methyl-3, 4-methylenedioxyamphetamine results in decreased expression of CYLD mRNA CTD PMID:26251327 4,4'-sulfonyldiphenol multiple interactions EXP 6480464 [bisphenol A co-treated with bisphenol F co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of CYLD mRNA CTD PMID:36041667 4-hydroxyphenyl retinamide decreases expression ISO RGD:1319184 6480464 Fenretinide results in decreased expression of CYLD mRNA CTD PMID:28973697 5-fluorouracil increases response to substance ISO RGD:1319183 6480464 CYLD protein results in increased susceptibility to Fluorouracil CTD PMID:21109933 acrylamide increases expression EXP 6480464 Acrylamide results in increased expression of CYLD mRNA CTD PMID:28959563 acrylamide increases expression ISO RGD:1319183 6480464 Acrylamide results in increased expression of CYLD mRNA CTD PMID:32763439 aflatoxin B1 increases expression ISO RGD:1319184 6480464 Aflatoxin B1 results in increased expression of CYLD mRNA CTD PMID:19770486 aflatoxin B1 increases methylation ISO RGD:1319183 6480464 Aflatoxin B1 results in increased methylation of CYLD exon CTD PMID:30157460 aflatoxin B1 increases expression ISO RGD:1319183 6480464 Aflatoxin B1 results in increased expression of CYLD mRNA CTD PMID:21641981 all-trans-retinoic acid increases expression ISO RGD:1319183 6480464 Tretinoin results in increased expression of CYLD mRNA CTD PMID:33167477 antirheumatic drug decreases expression ISO RGD:1319183 6480464 Antirheumatic Agents results in decreased expression of CYLD mRNA CTD PMID:24449571 aripiprazole multiple interactions ISO RGD:1319183 6480464 [Aripiprazole co-treated with Ozone] results in increased expression of CYLD mRNA CTD PMID:31476115 arsenous acid decreases expression ISO RGD:1319183 6480464 Arsenic Trioxide results in decreased expression of CYLD mRNA CTD PMID:15761015 atazanavir sulfate increases expression ISO RGD:1319183 6480464 Atazanavir Sulfate results in increased expression of CYLD mRNA CTD PMID:32152650 atazanavir sulfate multiple interactions ISO RGD:1319183 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 atrazine decreases expression EXP 6480464 Atrazine results in decreased expression of CYLD mRNA CTD PMID:36841081 benzo[a]pyrene increases expression ISO RGD:1319184 6480464 Benzo(a)pyrene results in increased expression of CYLD mRNA CTD PMID:20504355 benzo[a]pyrene multiple interactions ISO RGD:1319184 6480464 [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CYLD mRNA CTD PMID:27858113 benzo[b]fluoranthene multiple interactions ISO RGD:1319184 6480464 [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CYLD mRNA CTD PMID:27858113 bisphenol A decreases expression ISO RGD:1319183 6480464 bisphenol A results in decreased expression of CYLD mRNA CTD PMID:20678512 bisphenol A multiple interactions EXP 6480464 [bisphenol A co-treated with bisphenol F co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of CYLD mRNA CTD PMID:36041667 bisphenol A decreases methylation ISO RGD:1319183 6480464 bisphenol A results in decreased methylation of CYLD gene CTD PMID:31601247 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of CYLD mRNA CTD PMID:25181051 bisphenol A increases expression ISO RGD:1319184 6480464 bisphenol A results in increased expression of CYLD mRNA CTD PMID:20739668 , PMID:33221593 bisphenol A decreases expression ISO RGD:1319184 6480464 bisphenol A results in decreased expression of CYLD mRNA CTD PMID:20739668 bisphenol F multiple interactions EXP 6480464 [bisphenol A co-treated with bisphenol F co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of CYLD mRNA CTD PMID:36041667 butanal decreases expression ISO RGD:1319183 6480464 butyraldehyde results in decreased expression of CYLD mRNA CTD PMID:26079696 cannabidiol increases expression ISO RGD:1319183 6480464 Cannabidiol results in increased expression of CYLD mRNA CTD PMID:31801206 cannabidiol multiple interactions ISO RGD:1319183 6480464 [Cannabidiol co-treated with moringin] results in increased expression of CYLD mRNA CTD PMID:30096889 carbon nanotube decreases expression ISO RGD:1319184 6480464 Nanotubes more ... CTD PMID:25554681 CGP 52608 multiple interactions ISO RGD:1319183 6480464 CGP 52608 promotes the reaction [RORA protein binds to CYLD gene] CTD PMID:28238834 chenodeoxycholic acid multiple interactions ISO RGD:1319183 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA more ... CTD PMID:32152650 chlorpyrifos increases expression ISO RGD:1319184 6480464 Chlorpyrifos results in increased expression of CYLD mRNA CTD PMID:27737797 chlorpyrifos decreases expression ISO RGD:1319184 6480464 Chlorpyrifos results in decreased expression of CYLD mRNA CTD PMID:37019170 choline multiple interactions ISO RGD:1319184 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of CYLD gene CTD PMID:20938992 chrysene multiple interactions ISO RGD:1319184 6480464 [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CYLD mRNA CTD PMID:27858113 cisplatin increases response to substance ISO RGD:1319183 6480464 CYLD protein results in increased susceptibility to Cisplatin CTD PMID:21109933 cisplatin multiple interactions ISO RGD:1319183 6480464 [Cisplatin co-treated with jinfukang] results in decreased expression of CYLD mRNA CTD PMID:27392435 cisplatin increases expression ISO RGD:1319183 6480464 Cisplatin results in increased expression of CYLD mRNA CTD PMID:27594783 copper atom multiple interactions ISO RGD:1319183 6480464 [NSC 689534 binds to Copper] which results in increased expression of CYLD mRNA CTD PMID:20971185 copper(0) multiple interactions ISO RGD:1319183 6480464 [NSC 689534 binds to Copper] which results in increased expression of CYLD mRNA CTD PMID:20971185 crocidolite asbestos increases expression ISO RGD:1319183 6480464 Asbestos, Crocidolite results in increased expression of CYLD mRNA CTD PMID:18687144 crocidolite asbestos decreases expression ISO RGD:1319184 6480464 Asbestos, Crocidolite results in decreased expression of CYLD mRNA CTD PMID:29279043 cyclosporin A increases expression ISO RGD:1319183 6480464 Cyclosporine results in increased expression of CYLD mRNA CTD PMID:20106945 , PMID:32152650 cyclosporin A multiple interactions ISO RGD:1319183 6480464 [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 cyclosporin A decreases expression ISO RGD:1319183 6480464 Cyclosporine results in decreased expression of CYLD mRNA CTD PMID:25562108 cylindrospermopsin increases expression ISO RGD:1319183 6480464 cylindrospermopsin results in increased expression of CYLD mRNA CTD PMID:24921660 cypermethrin increases expression ISO RGD:1319183 6480464 cypermethrin results in increased expression of CYLD mRNA CTD PMID:27704156 deoxycholic acid multiple interactions ISO RGD:1319183 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA more ... CTD PMID:32152650 diarsenic trioxide decreases expression ISO RGD:1319183 6480464 Arsenic Trioxide results in decreased expression of CYLD mRNA CTD PMID:15761015 dicrotophos decreases expression ISO RGD:1319183 6480464 dicrotophos results in decreased expression of CYLD mRNA CTD PMID:28302478 dorsomorphin multiple interactions ISO RGD:1319183 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYLD mRNA CTD PMID:27188386 doxorubicin increases response to substance ISO RGD:1319183 6480464 CYLD protein results in increased susceptibility to Doxorubicin CTD PMID:21109933 doxorubicin increases expression ISO RGD:1319184 6480464 Doxorubicin results in increased expression of CYLD protein CTD PMID:36195186 doxorubicin increases expression EXP 6480464 Doxorubicin results in increased expression of CYLD protein CTD PMID:36195186 emodin increases expression ISO RGD:1319184 6480464 Emodin results in increased expression of CYLD mRNA CTD PMID:21319176 epoxiconazole decreases expression ISO RGD:1319184 6480464 epoxiconazole results in decreased expression of CYLD mRNA CTD PMID:35436446 ethanol affects splicing ISO RGD:1319184 6480464 Ethanol affects the splicing of CYLD mRNA CTD PMID:30319688 ethanol affects expression ISO RGD:1319184 6480464 Ethanol affects the expression of CYLD mRNA CTD PMID:30319688 ethyl methanesulfonate increases expression ISO RGD:1319183 6480464 Ethyl Methanesulfonate results in increased expression of CYLD mRNA CTD PMID:23649840 fenofibrate decreases expression ISO RGD:1319184 6480464 Fenofibrate results in decreased expression of CYLD mRNA CTD PMID:21318169 fenofibrate multiple interactions ISO RGD:1319184 6480464 PPARA protein affects the reaction [Fenofibrate results in decreased expression of CYLD mRNA] CTD PMID:21318169 fenthion decreases expression ISO RGD:1319184 6480464 Fenthion results in decreased expression of CYLD mRNA CTD PMID:34813904 folic acid multiple interactions ISO RGD:1319184 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of CYLD gene CTD PMID:20938992 formaldehyde increases expression ISO RGD:1319183 6480464 Formaldehyde results in increased expression of CYLD mRNA CTD PMID:23649840 furan increases methylation EXP 6480464 furan results in increased methylation of CYLD gene CTD PMID:22079235 gallic acid decreases expression ISO RGD:1319183 6480464 Gallic Acid results in decreased expression of CYLD mRNA CTD PMID:34408198 gentamycin increases expression EXP 6480464 Gentamicins results in increased expression of CYLD mRNA CTD PMID:33387578 glycochenodeoxycholic acid multiple interactions ISO RGD:1319183 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA more ... CTD PMID:32152650 glycocholic acid multiple interactions ISO RGD:1319183 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA more ... CTD PMID:32152650 glycodeoxycholic acid multiple interactions ISO RGD:1319183 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA more ... CTD PMID:32152650 glyphosate increases expression ISO RGD:1319183 6480464 glyphosate results in increased expression of CYLD mRNA CTD PMID:31874349 hexadecanoic acid increases expression EXP 6480464 Palmitic Acid results in increased expression of CYLD mRNA, Palmitic Acid results in increased expression of CYLD protein CTD PMID:34774660 hexadecanoic acid multiple interactions EXP 6480464 CYLD protein affects the reaction [Palmitic Acid results in decreased expression of CCND1 protein] more ... CTD PMID:34774660 L-methionine multiple interactions ISO RGD:1319184 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of CYLD gene CTD PMID:20938992 leflunomide decreases expression ISO RGD:1319183 6480464 leflunomide results in decreased expression of CYLD mRNA CTD PMID:28988120 lipopolysaccharide increases expression ISO RGD:1319183 6480464 Lipopolysaccharides results in increased expression of CYLD mRNA CTD PMID:35811015 lipopolysaccharide multiple interactions ISO RGD:1319183 6480464 [S-(1, 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of CYLD mRNA CTD PMID:35811015 methapyrilene increases expression EXP 6480464 Methapyrilene results in increased expression of CYLD mRNA CTD PMID:16393664 methidathion decreases expression ISO RGD:1319184 6480464 methidathion results in decreased expression of CYLD mRNA CTD PMID:34813904 methotrexate affects expression ISO RGD:1319184 6480464 Methotrexate affects the expression of CYLD mRNA CTD PMID:18502557 methyl methanesulfonate increases expression ISO RGD:1319183 6480464 Methyl Methanesulfonate results in increased expression of CYLD mRNA CTD PMID:23649840 methylmercury chloride decreases expression ISO RGD:1319183 6480464 methylmercuric chloride results in decreased expression of CYLD mRNA CTD PMID:28001369 methylseleninic acid increases expression ISO RGD:1319183 6480464 methylselenic acid results in increased expression of CYLD mRNA CTD PMID:18548127 nefazodone multiple interactions ISO RGD:1319183 6480464 [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 nefazodone increases expression ISO RGD:1319183 6480464 nefazodone results in increased expression of CYLD mRNA CTD PMID:32152650 nickel atom increases expression ISO RGD:1319183 6480464 Nickel results in increased expression of CYLD mRNA CTD PMID:24768652 ozone multiple interactions ISO RGD:1319183 6480464 [Aripiprazole co-treated with Ozone] results in increased expression of CYLD mRNA CTD PMID:31476115 ozone increases expression ISO RGD:1319183 6480464 Ozone results in increased expression of CYLD mRNA CTD PMID:31476115 paracetamol affects expression ISO RGD:1319184 6480464 Acetaminophen affects the expression of CYLD mRNA CTD PMID:17562736 paracetamol increases expression ISO RGD:1319183 6480464 Acetaminophen results in increased expression of CYLD mRNA CTD PMID:29067470 pentanal decreases expression ISO RGD:1319183 6480464 pentanal results in decreased expression of CYLD mRNA CTD PMID:26079696 perfluorooctane-1-sulfonic acid multiple interactions ISO RGD:1319184 6480464 [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of CYLD mRNA CTD PMID:36331819 pirinixic acid decreases expression ISO RGD:1319184 6480464 pirinixic acid results in decreased expression of CYLD mRNA CTD PMID:20813756 pirinixic acid multiple interactions ISO RGD:1319184 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of CYLD mRNA CTD PMID:19710929 raloxifene increases expression ISO RGD:1319184 6480464 Raloxifene Hydrochloride results in increased expression of CYLD mRNA CTD PMID:33269387 raloxifene multiple interactions ISO RGD:1319184 6480464 [SOD1 protein mutant form affects the susceptibility to Raloxifene Hydrochloride] which results in decreased expression of CYLD mRNA CTD PMID:33269387 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions ISO RGD:1319183 6480464 [S-(1, 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of CYLD mRNA CTD PMID:35811015 SB 431542 multiple interactions ISO RGD:1319183 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYLD mRNA CTD PMID:27188386 silicon dioxide increases expression ISO RGD:1319183 6480464 Silicon Dioxide results in increased expression of CYLD mRNA CTD PMID:25351596 sodium arsenite increases expression ISO RGD:1319183 6480464 sodium arsenite results in increased expression of CYLD protein alternative form CTD PMID:23562784 sodium arsenite affects methylation ISO RGD:1319183 6480464 sodium arsenite affects the methylation of CYLD gene CTD PMID:28589171 sodium arsenite multiple interactions ISO RGD:1319183 6480464 MIR2909 mRNA affects the reaction [sodium arsenite results in increased expression of CYLD protein alternative form] CTD PMID:23562784 sodium dichromate increases expression ISO RGD:1319183 6480464 sodium bichromate results in increased expression of CYLD mRNA CTD PMID:17685462 Soman decreases expression EXP 6480464 Soman results in decreased expression of CYLD mRNA CTD PMID:19281266 sorafenib increases expression ISO RGD:1319183 6480464 [sorafenib results in increased expression of CYLD protein] which results in increased expression of NFKBIA protein more ... CTD PMID:21109933 tetraphene multiple interactions ISO RGD:1319184 6480464 [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CYLD mRNA CTD PMID:27858113 thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of CYLD mRNA CTD PMID:34492290 triptonide affects expression ISO RGD:1319184 6480464 triptonide affects the expression of CYLD mRNA CTD PMID:33045310 tyrphostin AG 1478 increases expression ISO RGD:1319183 6480464 [RTKI cpd results in increased expression of CYLD protein] which results in increased expression of NFKBIA protein more ... CTD PMID:21109933 urethane increases expression ISO RGD:1319183 6480464 Urethane results in increased expression of CYLD mRNA CTD PMID:28818685 valproic acid increases expression EXP 6480464 Valproic Acid results in increased expression of CYLD mRNA CTD PMID:21318169 valproic acid multiple interactions ISO RGD:1319183 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYLD mRNA CTD PMID:27188386 valproic acid increases expression ISO RGD:1319183 6480464 Valproic Acid results in increased expression of CYLD mRNA CTD PMID:19101580 more ... valproic acid affects expression ISO RGD:1319183 6480464 Valproic Acid affects the expression of CYLD mRNA CTD PMID:25979313 vincristine increases expression ISO RGD:1319183 6480464 Vincristine results in increased expression of CYLD mRNA CTD PMID:23649840 vorinostat increases expression ISO RGD:1319183 6480464 vorinostat results in increased expression of CYLD mRNA CTD PMID:22083351 zinc atom multiple interactions ISO RGD:1319183 6480464 [PCI 5002 co-treated with Zinc] results in increased expression of CYLD mRNA CTD PMID:18593933 zinc(0) multiple interactions ISO RGD:1319183 6480464 [PCI 5002 co-treated with Zinc] results in increased expression of CYLD mRNA CTD PMID:18593933
